Remedy Robotics announced on November 16, 2026 that it had raised $62 million in Series B funding to advance clinical development and planned deployment of N1, its AI-enabled robotic platform for cardiovascular procedures. The capital will support a planned pivotal clinical trial with the University of California, advancement toward FDA approval for neurovascular intervention, and prototype N1 deployments across Remedy’s clinical-partner network. The company will also continue developing the…
Read the original article:
Remedy Robotics Raises $62M Series B to Advance AI Cardiovascular Care
